A group of scientists from the University of Alabama at Birmingham have derived predictive equations to identify adults at a high risk of having nocturnal hypertension or nondipping systolic blood pressure—both hard-to-catch conditions that can raise a person’s risk for CVD.

Taking a minimalist approach to transcatheter aortic valve implantation, which involves using conscious sedation in lieu of general anesthesia, could result in greater procedural efficiency and a comparable quality of life for patients.

Researchers studying ancient Inuit remains from Greenland have found that three in four mummies they analyzed showed signs of atherosclerosis, suggesting today’s CV hardships might not be the sole product of an unhealthy lifestyle in the 21st century.

Regular tea drinkers—especially those who favor green tea over black—lived longer and developed CVD later than non-habitual tea drinkers in a recent study of more than 100,000 people in China.

Blood pressure-monitoring technology is hitting the wearables market hard this year, and tech companies are vying to create the optimal tool for tracking BP on the go. But one company thinks they already have it figured out, according to CNET—in the form of BP-monitoring earbuds.

Taking steps to keep older patients’ systolic blood pressure under the 120 mmHg mark could lower those patients’ risk of MI, stroke, death and mild cognitive impairment, according to a new study—but it could also fast-track a decline in kidney health.

Drugmaker AstraZeneca announced Jan. 6 that its SGLT2 inhibitor dapagliflozin, sold commercially as Farxiga, had been granted Priority Review by the FDA for patients with heart failure with reduced ejection fraction.

The Heart Rhythm Society and Consumer Technology Association will debut new consumer guidelines this week focused on wearables that detect and monitor cardiovascular metrics.